We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
Recbio Technology has picked European CRO OCT Clinical to run a phase 3 trial of the Chinese biotech's COVID-19 vaccine.
The study will evaluate the vaccine in healthy patients aged 18 and upward who have not previously been vaccinated for COVID-19 and have not been infected with the virus in the past six months. Recbio is targeting as many as 10,000 volunteers but has only asked OCT to enroll 2,000 participants across 11 research sites.
OCT will be in charge of regulatory and logistics support, project management, volunteer recruitment and monitoring for the trial. The financial terms of the deal weren’t disclosed.
Read the full article at Fierce official website. [1]
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
